Abstract:We recently read the article by Tian et al with great interest.1 In their research, the authors compared the prognosis of patients with gastric and gastroesophageal junction adenocarcinoma who received perioperative chemoradiotherapy (PCRT) with those who received perioperative chemotherapy (POC) alone. The authors found that the addition of preoperative radiotherapy to POC appears to be associated with an increased risk of death in both the gastric and gastroesophageal junction adenocarcinoma subgroups. However, by reviewing previous studies and conducting an external validation based on the Surveillance, Epidemiology, and End Results (SEER) database, we found some contradicting results. Thus, we believe more caution should be exercised regarding any conclusions that additional radiotherapy increased the risk of death. In the majority of previous studies, a similar prognosis was demonstrated between the PCRT and the POC groups,2-4 a finding that contradicts the results published by Tian et al.1 Furthermore, if we focused on the patient with a T3 to T4 tumor, PCRT might have a positive influence on survival. For example, Stahl et al reported that in the Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET) trial (in which only patients with T3-T4 tumors were included),5 the PCRT group had a significantly improved progression-free survival (hazard ratio [HR], 0.37; P = .01) and the overall survival (OS) also demonstrated a positive trend (HR, 0.65; P = .055). Trying to investigate the result further, we conducted a validation study based on the SEER database, which also is nationwide. We included patients from 2004 through 2014 in the SEER database using the criteria of Tian et al.1 A total of 2201 patients finally were selected in our research, 934 of whom received PCRT and surgery, 336 of whom received POC, and 931 of whom underwent surgery alone. Pairwise 1:1 propensity score matching was performed to compare the survival outcomes among the 3 groups. It was shown that both the PCRT and the POC groups experienced a survival benefit compared with the group treated with surgery alone. However, there was no statistically significant difference noted with regard to the overall survival or cancer-specific survival between the PCRT and the POC groups. We also conducted a subgroup analysis using Cox regression. Within the population of patients with T3 to T4 disease, the PCRT group was found to have significantly improved prognosis compared with the surgery-alone group (HR, 0.44; 95% CI, 0.34-0.58 [P < .001]). Compared with the POC group, the result indicated a survival advantage for PCRT (HR, 0.74; 95% CI, 0.54-1.02 [P = .07]), although statistical significance was not achieved. In addition, it was shown that the PCRT group had a significantly better prognosis than both the POC and surgery-alone groups among patients with T3 to T4 disease and with positive lymph nodes (HRs of 0.65 and 0.44, respectively [P = .02 and P < .001, respectively]). Based on the above evidence, although the contradiction between the study by Tian et al1 and the previous ones remains difficult to explain, it is rational to assume that patients with advanced disease benefit more from radiotherapy. Thus, instead of concluding that radiotherapy may increase the risk, we believe a subgroup analysis is needed. In addition, the description of the tumor stage and patients' characteristics after propensity score matching may facilitate further discussion. No specific funding was disclosed. The authors made no disclosures.

Survival benefits of postoperative radiotherapy in patients with cT1 − 2N1M0 breast cancer after neoadjuvant chemotherapy: a SEER-based population study

Neoadjuvant Radiotherapy Improves Overall Survival for T3/4N+M0 Rectal Cancer Patients: a Population-Based Study of 20300 Patients

The Impact of Disparate Subtypes of Breast Cancer and Response to Postoperative Radiation Therapy in Neoadjuvant Setting

Influence of Radiation Therapy on the Outcome of T1-2N0M0 Triple-Negative Breast Cancer: A SEER Population-Based Retrospective Analysis.

Survival benefit of adjuvant therapy following neoadjuvant therapy in patients with resected esophageal cancer: a retrospective cohort study

Survival benefit after neoadjuvant or adjuvant radiotherapy for stage II–III gastroesophageal junction adenocarcinoma: A large population-based cohort study

Is postoperative adjuvant radiotherapy necessary for patients with esophageal cancer after neoadjuvant chemoradiotherapy? An analysis based on the SEER database

Neo-adjuvant radiation therapy provides a survival advantage in T3-T4 nodal positive gastric and gastroesophageal junction adenocarcinoma: a SEER database analysis

Palliative beam radiotherapy offered real-world survival benefit to metastatic rectal cancer: A large US population-based and propensity score-matched study.

Effect of Postoperative Radiotherapy for Squamous Cell Cancer of the Breast in A Surveillance Epidemiology and End Results Population-Based Study

Can Surgery Boost the Survival Benefit of Chemoradiotherapy in T1b1-T2a1 Stage Cervical Cancer with Lymph Node Metastasis? A Population-Based Study

Benefit of Postoperative Radiotherapy for Patients With Nonmetastatic Adrenocortical Carcinoma: A Population-Based Analysis

Patients with Gastroesophageal Junction Adenocarcinomas of an Advanced Stage May Benefit from Perioperative Chemoradiotherapy: A Validation Based on the Surveillance, Epidemiology, and End Results Database

Radiotherapy plays an important role in improving the survival outcome in patients with T1–2N1M0 breast cancer – a joint analysis of 4262 real world cases from two institutions

A Study of Postoperative Radiotherapy in Patients with Non–small-Cell Lung Cancer: a Randomized Trial

No survival benefit could be obtained from adjuvant radiotherapy in esophageal cancer treated with neoadjuvant chemotherapy followed by surgery: A SEER-based analysis

The Survival Benefit from the Addition of Radiation to Chemotherapy in Gastric Cancer Patients Following Surgical Resection.

Benefits of post-mastectomy radiation for T4N0M0 breast cancer patients: A SEER Database study

The effect of adjuvant radiotherapy after breast-conserving surgery in elderly women with T1-2N0 estrogen receptor-negative breast cancer

Efficacy of radiotherapy in patients with rectal cancer undergoing chemotherapy and surgery:a retrospective study based on the SEER database

Impact of Adjuvant Chemoradiotherapy on Survival of Resected Pancreatic Adenocarcinoma Cancer: A Surveillance, Epidemiology and End Results (SEER) Analysis